2019 Novel Coronavirus Clinical Trial
Official title:
A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)
Objective To determine the efficacy and safety of arbidol in patients with 2019 Novel Coronavirus (2019-nCoV).Methods Patients with 2019-nCoV were divided into three groups according to randomized double-blinded controlled clinical trial principle.Patients in three groups were administrated with arbidol,200mg,tid or arbidol,400 mg,tid or not for 5 days respectively. Other antiviral and comprehensive treatments of the three groups of patients are consistent. Then investigators will compare the first outcome: 28-day mortality, and secondary outcome: ICU hospitalization time, mechanical ventilation time, Hospitalization costs, antibiotic use costs, SOFA scores, CURB-65 scores, APACHE scores, and other clinical indicators.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04731051 -
The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients
|
Phase 1/Phase 2 | |
| Suspended |
NCT04334967 -
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
|
Phase 4 | |
| Recruiting |
NCT05113810 -
The Potential Use of Nebulized Hydroxychloroquine for the Treatment of COVID-19
|
Phase 2 |